Vaccine Prep (ATA)

A truly individualized cancer vaccine therapy that harnesses their body's own immune system to fight cancer

Personalized cancer vaccines are a groundbreaking approach to treatment in cancer care. Our Vaccine Prep (ATA) therapy stands at the forefront of this movement, offering patients a truly individualized cancer vaccine therapy that harnesses their body’s own immune system to fight cancer. This innovative personal cancer vaccine is a valuable advancement in autologous personalized cancer therapy, providing hope for patients seeking targeted, effective treatment options.

This therapy available to various countries (excluding Singapore).

What is Vaccine Prep (ATA)?

Vaccine Prep (ATA) is an advanced form of vaccine therapy for cancer that creates a personalized treatment specifically tailored to each patient’s unique cancer profile. This exciting approach represents the next generation of cancer vaccine technology, moving beyond traditional one-size-fits-all treatments to deliver truly individualized care.

CTCs and Tumor Cell Antigens
The foundation of our Vaccine prep therapy lies in the sophisticated analysis of circulating tumor cells (CTCs) found in a patient's blood. CTCs are cells that have broken off of the primary tumor and entered the bloodstream. What makes these cells particularly valuable for personalized cancer vaccines is their rich content of tumor-associated antigens (TAAs).

Tumor cells express an extensive array of both characterized and uncharacterized tumor-associated antigens. These antigens contain epitopes that can stimulate both CD8+ cytotoxic T cells (CTLs) and CD4+ T helper cells. This dual presentation of MHC Class I and II restricted antigens is crucial for generating a robust, comprehensive anti-tumor immune response and establishing long-term CD8+ T cell memory through CD4+ T helper cell activation.

Personalized Cancer Vaccine
What sets Vaccine Prep (ATA) apart as a personal cancer vaccine is its use of antigens derived directly from each patient's own tumor cells. Since tumor cells from each patient potentially carry unique gene mutations encoding for specific TAAs, this approach ensures that the vaccine is perfectly matched to the individual's cancer biology. This personalization is essential for stimulating effective and long-lasting anti-tumor responses that are specifically targeted to the patient's unique cancer profile.

How Does Vaccine Prep (ATA) Work?

Understanding the mechanism behind this cancer vaccine therapy helps illustrate why it represents such a significant advancement in personalized cancer therapy.

The process begins with a simple blood draw from the patient. From this blood sample, our advanced laboratory techniques isolate circulating tumor cells using sophisticated flow cytometry technology. This process achieves a robust sample of cells, providing an excellent foundation for creating the personalized cancer vaccine.

Every cancer is unique, even cancers of the same type occurring in the same organ. Each patient’s tumor cells carry specific genetic mutations and express particular proteins that make them distinct from both normal cells and other patients’ cancer cells. These unique characteristics, called tumor-associated antigens, serve as identifying markers that the immune system can learn to recognize and target.

The beauty of using one’s own tumor cells for vaccine therapy for cancer lies in this specificity. Rather than using generic antigens that may or may not be present in a patient’s particular cancer, Vaccine Prep (ATA) ensures that the immune system is trained to recognize the exact molecular signatures present in the patient’s specific tumor.

The isolated tumor cells undergo a carefully controlled process to create necrotic whole tumor cell lysate. This established method, already used in clinical trials, involves making the tumor cells necrotic through specialized techniques. The resulting material contains a comprehensive mixture of cellular components, including fragments of destroyed cellular membranes, intracellular organelles such as mitochondria, and cellular RNA and DNA.

This approach ensures that the cancer vaccine contains the complete spectrum of potential antigens present in the patient’s tumor, maximizing the chance of stimulating a broad and effective immune response.

While it might seem counterintuitive, necrotic tumor cells are actually superior to live tumor cells for personalized cancer vaccines. Live tumor cells are poorly immunogenic and can secrete soluble factors which can actually suppress the differentiation and maturation of dendritic cells – the very cells needed to present antigens to the immune system.

In contrast, necrotic tumor cells have been shown to induce partial maturation in dendritic cells without requiring additional maturation stimuli. This is likely due to the abundance of heat shock proteins released from dead cells during the necrosis process, which act as natural danger signals to alert the immune system.

Once administered, the personal cancer vaccine works by presenting the tumor antigens to the patient’s immune system in a way that promotes recognition and memory. Dendritic cells take up these antigens and present them to T cells, effectively “training” the immune system to recognize and attack cancer cells displaying these same antigens.

The parallel presentation of both MHC Class I and II restricted antigens helps generate a stronger overall anti-tumor response. CD8+ cytotoxic T cells directly attack cancer cells, while CD4+ T helper cells coordinate the immune response and help establish long-term immunological memory.

Seek help from our experts

Cancers Vaccine Prep (ATA) Can Treat

Vaccine Prep (ATA) has shown effectiveness in treating various types of solid tumors. This includes cancers such as:

- Breast cancer
- Lung cancer
- Colorectal cancer
- Prostate cancer
- Ovarian cancer
- Pancreatic cancer
- Liver cancer
- Kidney cancer
And other solid tumor types

The personalized cancer vaccine approach is particularly well-suited to solid tumors because these cancers shed circulating tumor cells into the bloodstream, providing the necessary starting material for vaccine creation.

Cancers Vaccine Prep (ATA) Cannot Treat

Certain types of cancers are not suitable for this cancer vaccine therapy, including:

- Hematologic cancers (blood cancers such as leukemia, lymphoma, and multiple myeloma)
- CNS cancers (central nervous system tumors)
- Testicular cancers
- Compartmentalized cancers that remain isolated within specific organs, such as brain tumors

These limitations are primarily due to the biology of these cancer types and their tendency not to shed circulating tumor cells in sufficient quantities for vaccine preparation.

Personalize your cancer journey

Reserve your 15-minute free one on one discussion

Why choose Vaccine Prep (ATA)?

Personalization: Unlike traditional treatments that take a one-size-fits-all approach, this personal cancer vaccine is created specifically for each patient's unique cancer biology.

Safety Profile: The use of the patient's own cellular material minimizes the risk of adverse reactions while maximizing compatibility.

Immune System Activation: Rather than suppressing the immune system like many conventional treatments, Vaccine Prep (ATA) works to strengthen and focus the body's natural cancer-fighting capabilities.

Comprehensive Antigen Presentation: The use of whole tumor cell lysate ensures exposure to the complete spectrum of tumor antigens, potentially providing broader protection against cancer recurrence.

Why choose Oncotrail?

Talk to our RGCC experts

WhatsApp me for the details of Vaccine Prep (ATA)

Frequently asked questions

What is the technology of Vaccine Prep (ATA)?

Vaccine Prep (ATA) is an advanced form of vaccine therapy for cancer that creates a personalized treatment specifically tailored to each patient's unique cancer profile.

At what cancer stage should a patient consider Vaccine Prep Therapy?

Is Vaccine Prep Therapy Safe?

What is the Treatment Schedule